Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New liquid biopsy could spot hidden brain lymphoma

NCT ID NCT06090162

Diagnosis Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a liquid biopsy (a simple test that checks for cancer DNA in spinal fluid) can better detect and monitor brain involvement in people with high-risk B-cell non-Hodgkin lymphoma. Researchers will compare this new method to standard tests in 64 newly diagnosed patients. If successful, it could help doctors decide who needs stronger treatment to prevent or manage lymphoma in the brain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent as documented by signature before registration and prior to any trial specific procedures, according to Swiss law and ICH E6 regulations Swiss law and ICH GCP E6(R2) regulations before registration. * Histologically and/or cytologically confirmed newly diagnosed lymphomas including the following: * Diffuse large B-cell lymphoma (DLBCL) with at least one of the following characteristics: * CNS IPI \> 4 * Non-GC/ABC subtype with IPI \> 3 * Testicular involvement * Breast involvement * Kidney involvement * Adrenal involvement * Paranasal sinus / orbit involvement * Involvement of ≥ 3 extranodal sites * HIV-positive * Radiological or histological CNS involvement * High-grade B-cell lymphoma with MYC translocation with BCL2 and / or BCL6 (HGBL) * Burkitt lymphoma * Mantle cell lymphoma (blastoid variant or Ki67 \>30% or TP53 mutated) * Primary CNS lymphoma Note: * Aggressive transformation from indolent lymphomas (pretreated or not) are allowed * Patients enrolled in other clinical trials may be included * Patients must be willing to undergo a lumbar puncture at screening * Age ≥ 18 years Exclusion Criteria: * Subtypes of Non-Hodgkin lymphoma (NHL) not fulfilling above mentioned criteria (e.g., indolent lymphoma, T-cell lymphoma) * Relapsing B-NHL * Low/intermediate-risk DLBCL (CNS-IPI \< 4) AND no CNS involvement on imaging * Any prior lymphoma-directed therapy before registration, with the exception of a maximum of 48 hours steroids prior to lumbar puncture procedure and therapies received for indolent lymphomas prior to transformation * Any active advanced or metastatic cancer * Any clinical contraindication to lumbar puncture procedure as per local guidelines * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned diagnostic procedure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burkitt lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma Burkitt lymphoma diffuse large B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement mantle cell lymphoma non-Hodgkin lymphoma primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma, B-cell

Contacts and locations

Locations

  • CHUV - Départment d'oncologie

    Lausanne, 1011, Switzerland

  • Hopitaux Universitaire de Genève (HUG)

    Geneva, 1205, Switzerland

  • Hôpital Fribourgeois - Hôpital Cantonal

    Fribourg, 1708, Switzerland

  • Hôpital du Valais, Hôpital de Sion

    Sion, 1951, Switzerland

  • Inselspital Bern - Universitätsklinik für Medizinische Onkologie

    Bern, 3010, Switzerland

  • Istituto Oncologico della Svizzera Italiana (IOSI)

    Bellinzona, 6500, Switzerland

  • Kantonspital Aarau

    Aarau, 5001, Switzerland

  • Kantonsspital Baselland

    Liestal, 4410, Switzerland

  • Kantonsspital Graubünden

    Chur, 7000, Switzerland

  • Kantonsspital Münsterlingen

    Münsterlingen, 8596, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Klinik für Hämatologie und Onkologie Hirslanden Zürich

    Zurich, 8032, Switzerland

  • Stadtspital Triemli Zürich

    Zurich, 8063, Switzerland

  • Universitätsspital Basel

    Basel, 4056, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.